Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Phase I/II Trial of an Individualized Peptide Vaccine in Pediatric and AYA Patients With Metastasized Fusion-driven Sarcomas Following Standard Treatment

NCT06094101 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT06094101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06094101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Phase I/II Trial of an Individualized Peptide Vaccine in Pediatric and AYA Patients With Metastasized Fusion-driven Sarcomas Following Standard Treatment
Lead sponsor
University Hospital Tuebingen
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 19, 2023
Completion date
September 30, 2027
Enrollment
30 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma, rhabdomyosarcoma, synovial sarcoma